Related Experiment Video
Updated: Mar 17, 2026

A Simple and Effective Method to Consistently Isolate Mouse Cardiomyocytes
Published on: November 11, 2022
Potential applications of catestatin in cardiovascular diseases
1The Departments of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Insights
Catestatin (CST) is a newly discovered factor involved in cardiovascular diseases. This review explores its protective role and mechanisms in heart conditions.
Area of Science:
- Biochemistry
- Cardiology
- Pharmacology
Background:
- Catestatin (CST) was identified in 1997 for its catecholamine-inhibitory activity.
- CST acts as a potent inhibitor of catecholamine secretion and regulates histamine release.
- Emerging evidence suggests CST's involvement in cardiovascular diseases, but its precise role remains unclear.
Purpose of the Study:
- To review current research on Catestatin (CST) and its association with cardiovascular diseases.
- To summarize findings from basic research and clinical trials concerning CST.
- To elucidate the potential protective mechanisms of CST in cardiovascular conditions.
Main Methods:
- Literature review of studies on CST and cardiovascular diseases.
- Inclusion of data from MedLine via PubMed searches.
- Incorporation of findings from the authors' own investigations.
Main Results:
- Accumulating evidence indicates CST's involvement in cardiovascular diseases.
- The exact protective role and mediating mechanisms of CST require further investigation.
- This review synthesizes existing knowledge on CST's cardiovascular implications.
Conclusions:
- CST is implicated in cardiovascular diseases, potentially offering a protective effect.
- Further research is needed to fully understand CST's mechanisms of action in cardiovascular health.
- Comprehensive review of existing data highlights the significance of CST in cardiology.
Abstract:
Catestatin (CST) was first named in 1997 for its catecholamine-inhibitory activity. It was discovered as a potent inhibitor of catecholamine secretion and as a regulator of histamine release. Accumulating evidence shows that CST is involved with cardiovascular diseases; however, whether CST is a protective factor for these conditions and the mechanisms by which such actions may be mediated are not well understood. In this article, we review recent basic research and clinical trials in the study of CST and summarize the association of CST with cardiovascular diseases. We review data obtained from MedLine via PubMed and from our own investigations.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
11:32Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
Published on: January 3, 2025
Related Concept Videos
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure Drugs: β-Blockers
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers